dipheyl ether | 62167-95-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: dipheyl ether
• 英文别名: Phenylalaninanhydrid；[(2S)-2-amino-3-phenylpropanoyl] (2S)-2-amino-3-phenylpropanoate
• CAS: 62167-95-7
• 化学式: C₁₈H₂₀N₂O₃
• 分子量: 312.368
• InChiKey: ZZDHJZADYBVFCP-HOTGVXAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  95.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  dipheyl ether 、 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  C32-amino derivatives of the immunosuppressant ascomycin

  摘要：

  Various C32-amino derivatives were investigated as replacements for the C32-hydroxyl group of ascomycin and its C24-deoxy analog. The syntheses of these amino derivatives and their biological evaluation are reported herein. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00409-5
• 作为产物：
  描述：

  BOC-L-苯丙氨酸 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 L-苯丙氨酸 、 dipheyl ether 、 Boc-Phe anhydride
  参考文献：
  名称：

  通过相控制的有机合成3.通过聚合物辅助反应由羧酸制得的对称酸酐。

  摘要：

  通过用4-乙烯基吡啶的固态共聚物处理羧酸和二分之一亚硫酰氯在二氯甲烷中的混合物，可以快速且高收率地生产对称酸酐。在批处理或列模式下，此转换同样可以很好地完成。

  DOI：

  10.1016/s0040-4039(00)85101-1
• 作为试剂：
  描述：

  2-苯基乙酰乙酸乙酯 、 3,5-二氯苯胺 在 溶剂黄146 作用下， 以 苯 、 dipheyl ether 为溶剂， 反应 0.25h， 以13%的产率得到5,7-dichloro-2-methyl-3-phenylquinolin-4(1H)-one
  参考文献：
  名称：

  Endochin Optimization: Structure−Activity and Structure−Property Relationship Studies of 3-Substituted 2-Methyl-4(1H)-quinolones with Antimalarial Activity

  摘要：

  Since the 1940s endochin and analogues thereof were known to be causal prophylactic and potent erythrocytic stage agents in avian models. Preliminary screening in a current in vitro assay identified several 4(1H)-quinolones with nanomolar EC(50) against erythrocytic stages of mullidrug resistant W2 and TM90-C2B isolates of Plasmodium folciparum. Follow-up structure activity relationship (SAR) studies on 4(1H)-quinolone analogues identified several key features for biological activity. Nevertheless, structure property relationship (SPR) studies conducted in parallel revealed that 4(1H)-quinolone analogues are limited by poor solubilities and rapid microsomal degradations. To improve the overall efficacy, multiple 4(1H)-quinolone series with varying substituents on the benzenoid quinolone ring and/or the 3-position were synthesized and tested for in vitro antimalarial activity. Several structurally diverse 6-chloro-2-methyl-7-methoxy-4(1H)-quinolones with EC(50) in the low nanomolar range against the clinically relevant isolates W2 and TM90-C2B were identified with improved physicochemical properties while maintaining little to no cross-resistance with atovaquone.

  DOI：

  10.1021/jm1007903

文献信息

• MEDICAL MATERIAL AND METHOD FOR MANUFACTURING SAME
  申请人：Ajinomoto Co., Inc.

  公开号：US20130266620A1

  公开（公告）日：2013-10-10

  The present invention aims to provide a medical material which is safe for the live body, has high biocompatibility and is useful for promotion of cell differentiation. The present invention produces a medical material for promoting cell differentiation, which contains polyamino acid as a main component, wherein the polyamino acid contains at least one kind of amino acid residue selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a glycine residue, a glutamine residue, an aspartic acid residue optionally containing a protecting group in the side chain, a tyrosine residue optionally containing a protecting group in the side chain, a tryptophan residue optionally containing a protecting group in the side chain, a lysine residue optionally containing a protecting group in the side chain, and a glutamic acid residue optionally containing a protecting group in the side chain.

  本发明旨在提供一种对生物体安全、具有高生物相容性并有助于促进细胞分化的医用材料。本发明生产一种促进细胞分化的医用材料，其主要成分为聚氨基酸，所述聚氨基酸含有从丙氨酸残基、缬氨酸残基、亮氨酸残基、异亮氨酸残基、苯丙氨酸残基、甘氨酸残基、谷氨酰胺残基、天冬酰胺酸残基（在侧链中可选含有保护基）、酪氨酸残基（在侧链中可选含有保护基）、色氨酸残基（在侧链中可选含有保护基）、赖氨酸残基（在侧链中可选含有保护基）和谷氨酸残基（在侧链中可选含有保护基）中至少选择一种氨基酸残基。
• New spergualin-related compound and pharmaceutical composition
  申请人：ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI

  公开号：EP0309971A2

  公开（公告）日：1989-04-05

  The present invention relates to new spergualin-related compounds having an immunopotentiating effect and represented by the general formula [I]: wherein X represents -(CH2)3-5- or R represents -H or -CH2-OH and R1 and R2 each represents a residue formed by removing a hydroxyl group from the carboxyl group of an amino acid or peptide with the proviso that both of R1 and R2 cannot represent at the same time, and pharmacologically acceptable salts thereof.

  本发明涉及具有免疫增强作用并由通式[I]表示的新的 spergualin 相关化合物： 其中 X 代表-(CH2)3-5-或 R代表-H或- -OH，R1和R2各自代表通过从氨基酸或肽的羧基上除去羟基而形成的残基，但R1和R2不能同时代表 的残基、 及其药理上可接受的盐类。
• Aminomacrolides and derivatives having immunosuppressive activity
  申请人：MERCK & CO. INC.

  公开号：EP0428365A1

  公开（公告）日：1991-05-22

  Aminomacrolides of the general structural Formula I: have been prepared from suitable precursors by incorporation of a nitrogen substituent at C-3˝ and/or C-4˝ of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses.

  通过在环己基环的 C-3˝ 和/或 C-4˝ 处加入氮取代基，已从合适的前体中制备出结构通式为 I： 通过在环己基环的 C-3˝ 和/或 C-4˝ 处加入氮取代基，从合适的前体中制备出了大环内酯类免疫抑制剂。这些大环内酯类免疫抑制剂可用于哺乳动物宿主治疗自身免疫性疾病、传染性疾病和/或预防外来器官移植的排斥反应。此外，这些大环内酯类免疫抑制剂还可用于局部治疗炎症性和过度增生性皮肤病以及免疫介导疾病的皮肤表现。
• Fluoromacrolides having immunosuppressive activity
  申请人：MERCK & CO. INC.

  公开号：EP0530888A1

  公开（公告）日：1993-03-10

  Fluoromacrolides and derivatives of the general structural Formula I: have been prepared from suitable precursors by oxidation and fluorination at C-20. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses. Also, these macrolides are useful in the treatment of reversible obstructive airways disease, particularly asthma. Furthermore, these macrolides are useful as hair revitalizing agents, especially in the treatment of male pattern alopecia or alopecia senilis.

  一般结构式 I 的氟茂霉素及其衍生物： 由合适的前体通过氧化和 C-20 处氟化制备而成。这些大环内酯类免疫抑制剂可用于哺乳动物宿主治疗自身免疫性疾病、传染性疾病和/或预防外来器官移植的排斥反应。此外，这些大环内酯类免疫抑制剂还可用于局部治疗炎症性和过度增生性皮肤病以及免疫介导疾病的皮肤表现。此外，这些大环内酯类药物还可用于治疗可逆性阻塞性气道疾病，尤其是哮喘。此外，这些大环内酯类药物还可用作活发剂，特别是用于治疗男性型脱发或老年性脱发。
• [EN] POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] TRAITEMENT DE TROUBLES NEUROLOGIQUES AU MOYEN DEPOLYAMINES
  申请人：MURPHY, Michael, A.

  公开号：WO1999008519A1

  公开（公告）日：1999-02-25

  (EN) 2,3,2 Tetramine (3,7-diazanonane-1,9-diamine) is propounded for the treatment of Parkinson's Disease and dementias characterized by mitochondrial damage in view of this compound's ability to completely neutralize the dopamine-depriving effect of MPTP in laboratory animals up to 12 hours post MPTP injection, and to retain partial protection at suboptimal tissue levels for up to 36 hours. The effect of injecting combinations of MPTP and/or reducing agents and/or xenobiotics and/or depigmenting agents on Dopamine, Norepinephrine, Serotonin and Epinephrine levels demonstrated that MPTP and MPP+ act as reducing agents that mobilize copper and calcium, and sequester iron, and that the vulnerability of dopaming to these types of neurotoxins and to xenobiotics and metals can be corrected by administration of 2,3,2 tetramine that appears to redistribute metals between diverse storage pools and free metals in cytosol and regulate receptor mediated events, among other antidotal effects analogous to those of some of the endogenous polyamines.(FR) La 2,3,2 Tétramine (3,7-diazanonane-1,9-diamine) est suggérée pour le traitement de la maladie de Parkinson et des démences caractérisées par des dommages de la mitochondrie, du fait de sa capacité à neutraliser intégralement les effets de suppression de la dopamine du MPTP chez les animaux de laboratoire jusqu'à 12 heures après l'injection de ce dernier, et à maintenir une protection partielle au niveau des tissus suboptimaux pendant une durée pouvant atteindre 36 heures. L'effet de l'injection de combinaisons de MPTP et/ou d'agents de réduction et/ou de xénobiotiques et/ou d'agents de dépigmentation sur les taux de dopamine, de nonrépinéphrine, de sérotonine et d'épinéphrine a démontré que MPTP et MPP+ agissent comme des agents de réduction qui mobilisent le cuivre et le calcium, et séquestrent le fer, et que la sensibilité de la dopamine à ces types de neurotoxines, aux xénobiotiques et au métaux peut être corrigée par l'administration de 2,3,2 tétramine, laquelle semble redistribuer les métaux entre les divers groupes d'unités de stockage et les métaux libres dans le cytosol et semble réguler les événements induits par les récepteurs, parmi d'autres effets antidotaux analogues à ceux de certaines polyamines endogènes.

  2,3,2-丁胺（3,7-二硝基烷-1,9-二胺）被建议用于治疗由线粒体损伤引起的 parkinson 病和退行性疾病。该化合物因其在实验动物中能够完全中和 MPTP 对多巴胺剥夺效应的能力，在 MPTP 注射后 12小时内以及在非优级组织水平下保持部分保护作用高达 36 小时。注射 MPTP 和或还原剂和/或外毒素和/或脱色剂的组合对 Dopamine、非烯丙胺、 Serotonin 和 Epinephrine 浓度的影响显示，MPTP和 MPP+ 作为易于促进铜和钙的转运，并沉淀铁的还原剂。并且通过注射 2,3,2-丁胺，可以纠正多巴胺对这些神经毒物、外毒素和金属的易变性，这种作用似乎使金属在不同储存单元和细胞溶中的自由金属之间重新分配，并调节受体介导的事件，以及其他类似于某些内源性多胺的抗毒素效应。